Extracellular matrix molecules implicated in hypertrophic and keloid scarring

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 2, 2012, Pages 141-152

  Sidgwick, G P ^a   Bayat, A ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; DECORIN; ELASTIN; FIBRILLIN; FIBROMODULIN; FIBRONECTIN; HYALURONIC ACID; LAMININ; LUMICAN; TENASCIN; TRANSCRIPTION FACTOR RUNX2;

EXTRACELLULAR MATRIX; HUMAN; HYPERTROPHIC SCAR; KELOID; MEDLINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; REVIEW; SYSTEMATIC REVIEW; WOUND HEALING;

CICATRIX, HYPERTROPHIC; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; GLYCOSAMINOGLYCANS; HUMANS; HYALURONIC ACID; KELOID; PROTEOGLYCANS;

EID: 84856340426     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04200.x     Document Type: Review

References (124)

1. Bouwstra JA, Ponec M,. The skin barrier in healthy and diseased state. Biochim Biophys Acta 2006; 1758: 2080-2095. (Pubitemid 44879362)
2. Proksch E, Brandner JM, Jensen JM,. The skin: an indispensable barrier. Exp Dermatol 2008; 17: 1063-1072.
3. Lee SH, Jeong SK, Ahn SK,. An update of the defensive barrier function of skin. Yonsei Med J 2006; 47: 293-306. (Pubitemid 43984155)
4. Nemes Z, Steinert PM,. Bricks and mortar of the epidermal barrier. Exp Mol Med 1999; 31: 5-19. (Pubitemid 29164098)
5. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R,. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61: 198-223.
6. Sandjeu Y, Haftek M,. Desmosealin and other components of the epidermal extracellular matrix. J Physiol Pharmacol 2009; 60 (Suppl. 4): 23-30.
7. Thomas DW, O'Neill ID, Harding KG, Shepherd JP,. Cutaneous wound healing: a current perspective. J Oral Maxillofac Surg 1995; 53: 442-447.
8. Slemp AE, Kirschner RE,. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr 2006; 18: 396-402. (Pubitemid 44258997)
9. Schultz GS, Wysocki A,. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009; 17: 153-162.
10. Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ,. Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol 1997; 29: 5-17. (Pubitemid 27096415)
11. Bran GM, Goessler UR, Hormann K, Riedel F, Sadick H,. Keloids: current concepts of pathogenesis (review). Int J Mol Med 2009; 24: 283-293.
12. Shih B, Garside E, McGrouther DA, Bayat A,. Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair Regen 2010; 18: 139-153.
13. Eming SA, Krieg T, Davidson JM,. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007; 127: 514-525.
14. Clark RA,. Fibrin and wound healing. Ann N Y Acad Sci 2001; 936: 355-367. (Pubitemid 32613921)
15. Burd A, Huang L,. Hypertrophic response and keloid diathesis: two very different forms of scar. Plast Reconstr Surg 2005; 116: 150e-157e.
16. Durani P, McGrouther DA, Ferguson MW,. The Patient Scar Assessment Questionnaire: a reliable and valid patient-reported outcomes measure for linear scars. Plast Reconstr Surg 2009; 123: 1481-1489.
17. Sullivan T, Smith J, Kermode J, McIver E, Courtemanche DJ,. Rating the burn scar. J Burn Care Rehabil 1990; 11: 256-260.
18. Beausang E, Floyd H, Dunn KW, Orton CI, Ferguson MW,. A new quantitative scale for clinical scar assessment. Plast Reconstr Surg 1998; 102: 1954-1961. (Pubitemid 28518519)
19. Bayat A, McGrouther DA, Ferguson MW,. Skin scarring. BMJ 2003; 326: 88-92. (Pubitemid 36092292)
20. Marneros AG, Krieg T,. Keloids-clinical diagnosis, pathogenesis, and treatment options. J Dtsch Dermatol Ges 2004; 2: 905-913. (Pubitemid 39472352)
21. Tuan TL, Nichter LS,. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998; 4: 19-24. (Pubitemid 28124795)
22. Thomas DW, Hopkinson I, Harding KG, Shepherd JP,. The pathogenesis of hypertrophic/keloid scarring. Int J Oral Maxillofac Surg 1994; 23: 232-236.
23. Kose O, Waseem A,. Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol Surg 2008; 34: 336-346. (Pubitemid 351316825)
24. Wilson CL, Burge SM, Dean D, Dawber RP,. Scarring alopecia in discoid lupus erythematosus. Br J Dermatol 1992; 126: 307-314.
25. Mizutani H, Taniguchi H, Sakakura T, Shimizu M,. Nodular scleroderma: focally increased tenascin expression differing from that in the surrounding scleroderma skin. J Dermatol 1995; 22: 267-271.
26. Bissell DM,. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 2001; 33: 179-190. (Pubitemid 34534275)
27. Neudecker BA, Stern R, Connolly MK,. Aberrant serum hyaluronan and hyaluronidase levels in scleroderma. Br J Dermatol 2004; 150: 469-476. (Pubitemid 38446301)
28. Saika S, Yamanaka O, Sumioka T, et al. Fibrotic disorders in the eye: targets of gene therapy. Prog Retin Eye Res 2008; 27: 177-196.
29. Meenakshi J, Vidyameenakshi S, Ananthram D, Ramakrishnan KM, Jayaraman V, Babu M,. Low decorin expression along with inherent activation of ERK1,2 in ear lobe keloids. Burns 2009; 35: 519-526.
30. Verhaegen PD, van Zuijlen PP, Pennings NM, et al. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: an objective histopathological analysis. Wound Repair Regen 2009; 17: 649-656.
31. Friedman DW, Boyd CD, Mackenzie JW, Norton P, Olson RM, Deak SB,. Regulation of collagen gene expression in keloids and hypertrophic scars. J Surg Res 1993; 55: 214-222. (Pubitemid 23335800)
32. Gosiewska A, Yi CF, Brown LJ, Cullen B, Silcock D, Geesin JC,. Differential expression and regulation of extracellular matrix-associated genes in fetal and neonatal fibroblasts. Wound Repair Regen 2001; 9: 213-222. (Pubitemid 32706269)
33. Smith LT, Holbrook KA, Madri JA,. Collagen types I, III, and V in human embryonic and fetal skin. Am J Anat 1986; 175: 507-521. (Pubitemid 16071673)
34. Syed F, Ahmadi E, Iqbal SA, Singh S, McGrouther DA, Bayat A,. Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III expression compared to intra- and extra-lesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol 2010; 164: 83-96.
35. Naitoh M, Hosokawa N, Kubota H, et al. Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid. Biochem Biophys Res Commun 2001; 280: 1316-1322. (Pubitemid 32917787)
36. Occleston NL, Laverty HG, O'Kane S, Ferguson MW,. Prevention and reduction of scarring in the skin by transforming growth factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical. J Biomater Sci Polym Ed 2008; 19: 1047-1063. (Pubitemid 351957390)
37. Daian T, Ohtsuru A, Rogounovitch T, et al. Insulin-like growth factor-I enhances transforming growth factor-beta-induced extracellular matrix protein production through the P38/activating transcription factor-2 signaling pathway in keloid fibroblasts. J Invest Dermatol 2003; 120: 956-962. (Pubitemid 36702903)
38. Bock O, Yu H, Zitron S, Bayat A, Ferguson MW, Mrowietz U,. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. Acta Derm Venereol 2005; 85: 216-220. (Pubitemid 40695163)
39. Makino S, Mitsutake N, Nakashima M, et al. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. J Dermatol Sci 2008; 51: 171-180.
40. Lim IJ, Phan TT, Bay BH, et al. Fibroblasts cocultured with keloid keratinocytes: normal fibroblasts secrete collagen in a keloidlike manner. Am J Physiol Cell Physiol 2002; 283: C212-C222. (Pubitemid 34670565)
41. Phan TT, Lim IJ, Bay BH, et al. Differences in collagen production between normal and keloid-derived fibroblasts in serum-media co-culture with keloid-derived keratinocytes. J Dermatol Sci 2002; 29: 26-34. (Pubitemid 34462189)
42. Kielty CM, Sherratt MJ, Shuttleworth CA,. Elastic fibres. J Cell Sci 2002; 115: 2817-2828.
43. Amadeu TP, Braune AS, Porto LC, Desmouliere A, Costa AM,. Fibrillin-1 and elastin are differentially expressed in hypertrophic scars and keloids. Wound Repair Regen 2004; 12: 169-174. (Pubitemid 38520683)
44. Kozma EM, Olczyk K, Glowacki A, Bobinski R,. An accumulation of proteoglycans in scarred fascia. Mol Cell Biochem 2000; 203: 103-112. (Pubitemid 30111782)
45. Evanko SP, Tammi MI, Tammi RH, Wight TN,. Hyaluronan-dependent pericellular matrix. Adv Drug Deliv Rev 2007; 59: 1351-1365. (Pubitemid 350088257)
46. Phan TT, Lim IJ, Aalami O, et al. Smad3 signalling plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions. J Pathol 2005; 207: 232-242. (Pubitemid 41404154)
47. Meran S, Thomas DW, Stephens P, et al. Hyaluronan facilitates transforming growth factor-beta1-mediated fibroblast proliferation. J Biol Chem 2008; 283: 6530-6545.
48. Tan KT, McGrouther DA, Day AJ, Milner CM, Bayat A,. Characterization of hyaluronan and TSG-6 in skin scarring: differential distribution in keloid scars, normal scars and unscarred skin. J Eur Acad Dermatol Venereol 2011; 25: 317-327.
49. Coolen NA, Schouten KC, Middelkoop E, Ulrich MM,. Comparison between human fetal and adult skin. Arch Dermatol Res 2010; 302: 47-55.
50. Larson BJ, Longaker MT, Lorenz HP,. Scarless fetal wound healing: a basic science review. Plast Reconstr Surg 2010; 126: 1172-1180.
51. Namazi MR, Fallahzadeh MK, Schwartz RA,. Strategies for prevention of scars: what can we learn from fetal skin? Int J Dermatol 2011; 50: 85-93.
52. DePalma RL, Krummel TM, Durham LA 3rd, et al. Characterization and quantitation of wound matrix in the fetal rabbit. Matrix 1989; 9: 224-231. (Pubitemid 19178990)
53. Sawai T, Usui N, Sando K, et al. Hyaluronic acid of wound fluid in adult and fetal rabbits. J Pediatr Surg 1997; 32: 41-43. (Pubitemid 27057024)
54. Andre P,. Hyaluronic acid and its use as a "rejuvenation" agent in cosmetic dermatology. Semin Cutan Med Surg 2004; 23: 218-222. (Pubitemid 43180995)
55. Cabrera RC, Siebert JW, Eidelman Y, Gold LI, Longaker MT, Garg HG,. The in vivo effect of hyaluronan associated protein-collagen complex on wound repair. Biochem Mol Biol Int 1995; 37: 151-158. (Pubitemid 26177887)
56. Mast BA, Diegelmann RF, Krummel TM, Cohen IK,. Hyaluronic acid modulates proliferation, collagen and protein synthesis of cultured fetal fibroblasts. Matrix 1993; 13: 441-446.
57. Meyer LJ, Russell SB, Russell JD, et al. Reduced hyaluronan in keloid tissue and cultured keloid fibroblasts. J Invest Dermatol 2000; 114: 953-959. (Pubitemid 30252717)
58. Bertheim U, Hellstrom S,. The distribution of hyaluronan in human skin and mature, hypertrophic and keloid scars. Br J Plast Surg 1994; 47: 483-489. (Pubitemid 24309460)
59. Sanggaard KW, Sonne-Schmidt CS, Krogager TP, et al. TSG-6 transfers proteins between glycosaminoglycans via a Ser28-mediated covalent catalytic mechanism. J Biol Chem 2008; 283: 33919-33926.
60. Milner CM, Tongsoongnoen W, Rugg MS, Day AJ,. The molecular basis of inter-alpha-inhibitor heavy chain transfer on to hyaluronan. Biochem Soc Trans 2007; 35: 672-676. (Pubitemid 47310338)
61. Rugg MS, Willis AC, Mukhopadhyay D, et al. Characterization of complexes formed between TSG-6 and inter-alpha-inhibitor that act as intermediates in the covalent transfer of heavy chains onto hyaluronan. J Biol Chem 2005; 280: 25674-25686. (Pubitemid 40962277)
62. Lim IJ, Phan TT, Tan EK, et al. Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloids. J Biol Chem 2003; 278: 40851-40858. (Pubitemid 37280903)
63. Babu M, Diegelmann R, Oliver N,. Fibronectin is overproduced by keloid fibroblasts during abnormal wound healing. Mol Cell Biol 1989; 9: 1642-1650. (Pubitemid 19095205)
64. Kischer CW, Hendrix MJ,. Fibronectin (FN) in hypertrophic scars and keloids. Cell Tissue Res 1983; 231: 29-37. (Pubitemid 13054902)
65. Kischer CW, Wagner HN Jr, Pindur J, et al. Increased fibronectin production by cell lines from hypertrophic scar and keloid. Connect Tissue Res 1989; 23: 279-288.
66. Sible JC, Eriksson E, Smith SP, Smith N,. Fibronectin gene expression differs in normal and abnormal human wound healing. Wound Repair Regen 1994; 2: 3-19.
67. Nagata H, Ueki H, Moriguchi T,. Fibronectin. Localization in normal human skin, granulation tissue, hypertrophic scar, mature scar, progressive systemic sclerotic skin, and other fibrosing dermatoses. Arch Dermatol 1985; 121: 995-999. (Pubitemid 15014937)
68. Dalkowski A, Schuppan D, Orfanos CE, Zouboulis CC,. Increased expression of tenascin C by keloids in vivo and in vitro. Br J Dermatol 1999; 141: 50-56. (Pubitemid 29333693)
69. Durbeej M,. Laminins. Cell Tissue Res 2010; 339: 259-268.
70. Jones JC, Dehart GW, Gonzales M, Goldfinger LE,. Laminins: an overview. Microsc Res Tech 2000; 51: 211-213.
71. Andriessen MP, Niessen FB, Van de Kerkhof PC, Schalkwijk J,. Hypertrophic scarring is associated with epidermal abnormalities: an immunohistochemical study. J Pathol 1998; 186: 192-200. (Pubitemid 28467830)
72. Kuroda K, Okamoto O, Shinkai H,. Dermatopontin expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is regulated by transforming growth factor-beta1, interleukin-4, and matrix collagen. J Invest Dermatol 1999; 112: 706-710. (Pubitemid 29220711)
73. Catherino WH, Leppert PC, Stenmark MH, et al. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 2004; 40: 204-217. (Pubitemid 38703097)
74. Russell SB, Russell JD, Trupin KM, et al. Epigenetically altered wound healing in keloid fibroblasts. J Invest Dermatol 2010; 130: 2489-2496.
75. Zhou HM, Wang J, Elliott C, Wen W, Hamilton DW, Conway SJ,. Spatiotemporal expression of periostin during skin development and incisional wound healing: lessons for human fibrotic scar formation. J Cell Commun Signal 2010; 4: 99-107.
76. Jackson-Boeters L, Wen W, Hamilton DW,. Periostin localizes to cells in normal skin, but is associated with the extracellular matrix during wound repair. J Cell Commun Signal 2009; 3: 125-133.
77. Norris RA, Damon B, Mironov V, et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem 2007; 101: 695-711. (Pubitemid 46698854)
78. Chiquet-Ehrismann R, Chiquet M,. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003; 200: 488-499. (Pubitemid 36818249)
79. O'Connell M, Burrows NP, van Vlijmen-Willems MJ, Clark SM, Schalkwijk J,. Tenascin-X deficiency and Ehlers-Danlos syndrome: a case report and review of the literature. Br J Dermatol 2010; 163: 1340-1345.
80. Sible JC, Rettig WJ, Eriksson E, Smith SP, Oliver N,. Gene expression of tenascin is altered in normal scars and keloids. Wound Repair Regen 1995; 3: 37-48.
81. Knaggs HE, Layton AM, Morris C, Wood EJ, Holland DB, Cunliffe WJ,. Investigation of the expression of the extracellular matrix glycoproteins tenascin and fibronectin during acne vulgaris. Br J Dermatol 1994; 130: 576-582. (Pubitemid 24204692)
82. Whitby DJ, Longaker MT, Harrison MR, Adzick NS, Ferguson MW,. Rapid epithelialisation of fetal wounds is associated with the early deposition of tenascin. J Cell Sci 1991; 99: 583-586.
83. Honardoust D, Eslami A, Larjava H, Hakkinen L,. Localization of small leucine-rich proteoglycans and transforming growth factor-beta in human oral mucosal wound healing. Wound Repair Regen 2008; 16: 814-823.
84. Sayani K, Dodd CM, Nedelec B, et al. Delayed appearance of decorin in healing burn scars. Histopathology 2000; 36: 262-272. (Pubitemid 30145254)
85. Beanes SR, Dang C, Soo C, et al. Down-regulation of decorin, a transforming growth factor-beta modulator, is associated with scarless fetal wound healing. J Pediatr Surg 2001; 36: 1666-1671. (Pubitemid 33021988)
86. Hunzelmann N, Anders S, Sollberg S, Schonherr E, Krieg T,. Co-ordinate induction of collagen type I and biglycan expression in keloids. Br J Dermatol 1996; 135: 394-399. (Pubitemid 26297834)
87. Wang J, Dodd C, Shankowsky HA, Scott PG, Tredget EE,. Deep dermal fibroblasts contribute to hypertrophic scarring. Lab Invest 2008; 88: 1278-1290.
88. Kirn-Safran C, Farach-Carson MC, Carson DD,. Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. Cell Mol Life Sci 2009; 66: 3421-3434.
89. Mukhopadhyay A, Wong MY, Chan SY, et al. Syndecan-2 and decorin: proteoglycans with a difference-implications in keloid pathogenesis. J Trauma 2010; 68: 999-1008.
90. Barker TH, Baneyx G, Cardo-Vila M, et al. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem 2005; 280: 36483-36493. (Pubitemid 41633922)
91. Kyriakides TR, Tam JW, Bornstein P,. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 1999; 113: 782-787.
92. Paddock HN, Schultz GS, Baker HV, et al. Analysis of gene expression patterns in human postburn hypertrophic scars. J Burn Care Rehabil 2003; 24: 371-377. (Pubitemid 37444513)
93. Chipev CC, Simman R, Hatch G, Katz AE, Siegel DM, Simon M,. Myofibroblast phenotype and apoptosis in keloid and palmar fibroblasts in vitro. Cell Death Differ 2000; 7: 166-176. (Pubitemid 30150784)
94. Brown JJ, Bayat A,. Genetic susceptibility to raised dermal scarring. Br J Dermatol 2009; 161: 8-18.
95. Shih B, Bayat A,. Genetics of keloid scarring. Arch Dermatol Res 2010; 302: 319-339.
96. Naitoh M, Kubota H, Ikeda M, et al. Gene expression in human keloids is altered from dermal to chondrocytic and osteogenic lineage. Genes Cells 2005; 10: 1081-1091. (Pubitemid 41556076)
97. Satish L, Lyons-Weiler J, Hebda PA, Wells A,. Gene expression patterns in isolated keloid fibroblasts. Wound Repair Regen 2006; 14: 463-470. (Pubitemid 44266604)
98. Shih B, McGrouther DA, Bayat A,. Identification of novel keloid biomarkers through profiling of tissue biopsies versus cell cultures in keloid margin specimens compared to adjacent normal skin. Eplasty 2010; 10: e24.
99. Seifert O, Bayat A, Geffers R, et al. Identification of unique gene expression patterns within different lesional sites of keloids. Wound Repair Regen 2008; 16: 254-265. (Pubitemid 351342120)
100. Tsou R, Cole JK, Nathens AB, et al. Analysis of hypertrophic and normal scar gene expression with cDNA microarrays. J Burn Care Rehabil 2000; 21: 541-550. (Pubitemid 32050421)
101. Smith JC, Boone BE, Opalenik SR, Williams SM, Russell SB,. Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J Invest Dermatol 2008; 128: 1298-1310. (Pubitemid 351543197)
102. Chen W, Fu X, Sun X, Sun T, Zhao Z, Sheng Z,. Analysis of differentially expressed genes in keloids and normal skin with cDNA microarray. J Surg Res 2003; 113: 208-216. (Pubitemid 37040891)
103. Chen W, Fu XB, Ge SL, et al. Development of gene microarray in screening differently expressed genes in keloid and normal-control skin. Chin Med J (Engl) 2004; 117: 877-881. (Pubitemid 38961683)
104. Luo X, Pan Q, Liu L, Chegini N,. Genomic and proteomic profiling II: comparative assessment of gene expression profiles in leiomyomas, keloids, and surgically-induced scars. Reprod Biol Endocrinol 2007; 5: 35.
105. Ong CT, Khoo YT, Mukhopadhyay A, et al. Comparative proteomic analysis between normal skin and keloid scar. Br J Dermatol 2010; 162: 1302-1315.
106. Tran KT, Griffith L, Wells A,. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen 2004; 12: 262-268. (Pubitemid 38880434)
107. Chung HJ, Steplewski A, Chung KY, Uitto J, Fertala A,. Collagen fibril formation. A new target to limit fibrosis. J Biol Chem 2008; 283: 25879-25886.
108. Tanriverdi-Akhisaroglu S, Menderes A, Oktay G,. Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: a pilot study. Cell Biochem Funct 2009; 27: 81-87.
109. Uchida G, Yoshimura K, Kitano Y, Okazaki M, Harii K,. Tretinoin reverses upregulation of matrix metalloproteinase-13 in human keloid-derived fibroblasts. Exp Dermatol 2003; 12 (Suppl. 2): 35-42. (Pubitemid 37526847)
110. Ulrich D, Ulrich F, Unglaub F, Piatkowski A, Pallua N,. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids. J Plast Reconstr Aesthet Surg 2010; 63: 1015-1021.
111. Bran GM, Goessler UR, Baftiri A, Hormann K, Riedel F, Sadick H,. Effect of transforming growth factor-beta1 antisense oligonucleotides on matrix metalloproteinases and their inhibitors in keloid fibroblasts. Otolaryngol Head Neck Surg 2010; 143: 66-71.
112. Imaizumi R, Akasaka Y, Inomata N, et al. Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: implications for mechanisms of keloid progression. Histopathology 2009; 54: 722-730.
113. Moali C, Hulmes DJ,. Extracellular and cell surface proteases in wound healing: new players are still emerging. Eur J Dermatol 2009; 19: 552-564.
114. Steinbrech DS, Mehrara BJ, Chau D, et al. Hypoxia upregulates VEGF production in keloid fibroblasts. Ann Plast Surg 1999; 42: 514-519 discussion 9-20.
115. Wu Y, Zhang Q, Ann DK, et al. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. Am J Physiol Cell Physiol 2004; 286: C905-C912. (Pubitemid 38543819)
116. Zhang Q, Oh CK, Messadi DV, et al. Hypoxia-induced HIF-1 alpha accumulation is augmented in a co-culture of keloid fibroblasts and human mast cells: involvement of ERK1/2 and PI-3K/Akt. Exp Cell Res 2006; 312: 145-155. (Pubitemid 41721177)
117. Zhang Q, Wu Y, Ann DK, et al. Mechanisms of hypoxic regulation of plasminogen activator inhibitor-1 gene expression in keloid fibroblasts. J Invest Dermatol 2003; 121: 1005-1012. (Pubitemid 37430966)
118. Lane JE, Waller JL, Davis LS,. Relationship between age of ear piercing and keloid formation. Pediatrics 2005; 115: 1312-1314.
119. Ashcroft GS, Horan MA, Ferguson MW,. The effects of ageing on cutaneous wound healing in mammals. J Anat 1995; 187: 1-26.
120. Harunari N, Zhu KQ, Armendariz RT, et al. Histology of the thick scar on the female, red Duroc pig: final similarities to human hypertrophic scar. Burns 2006; 32: 669-677.
121. Gallant-Behm CL, Olson ME, Hart DA,. Cytokine and growth factor mRNA expression patterns associated with the hypercontracted, hyperpigmented healing phenotype of red duroc pigs: a model of abnormal human scar development? J Cutan Med Surg 2005; 9: 165-177.
122. Zhu KQ, Engrav LH, Tamura RN, et al. Further similarities between cutaneous scarring in the female, red Duroc pig and human hypertrophic scarring. Burns 2004; 30: 518-530.
123. Cass DL, Bullard KM, Sylvester KG, et al. Epidermal integrin expression is upregulated rapidly in human fetal wound repair. J Pediatr Surg 1998; 33: 312-316.
124. Lygoe KA, Wall I, Stephens P, Lewis MP,. Role of vitronectin and fibronectin receptors in oral mucosal and dermal myofibroblast differentiation. Biol Cell 2007; 99: 601-614. (Pubitemid 350120980)